MedRx Co., Ltd Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Consolidated and Non-Consolidated Earnings Guidance for the Six Months Ending Jun. 2015 and for the Year Ending December 31, 2015
February 13, 2015 at 08:58 pm IST
Share
MedRx Co. Ltd. announced consolidated and non-consolidated earnings results for the year ended December 31, 2014. For the year, the group reported net sales of ¥26 million, operating loss of ¥1,003 million, ordinary loss of ¥1,012 million and net loss of ¥1,016 million or ¥151.96 per share compared to net sales of ¥68 million, operating loss of ¥604 million, ordinary loss of ¥616 million and net loss of ¥621 million or ¥113.48 per share reported in the same period last year. Negative return on equity was 25.4% against 26.0% reported last year. Cash used in operating activities was ¥931 million against ¥613 million reported last year.
For the year ending December 31, 2015, the group expected to report net sales of ¥18 million, operating loss of ¥1,035 million, ordinary loss of ¥890 million and net loss of ¥894 million or ¥133.73 per share.
For the six months ending Jun. 2015, the group expected to report net sales of ¥9 million, operating loss of ¥501 million, ordinary loss of ¥374 million and net loss of ¥376 million or ¥56.29 per share.
For the year, the parent company reported net sales of ¥26 million, operating loss of ¥1,010 million, ordinary loss of ¥996 million and net loss of ¥1,001 million or ¥149.70 per diluted share compared to net sales of ¥68 million, operating loss of ¥611 million, ordinary loss of ¥594 million and net loss of ¥598 million or ¥109.25 per diluted share reported in the same period last year.
For the year ending December 31, 2015, the parent company expected to report net sales of ¥18 million, ordinary loss of ¥898 million and net loss of ¥902 million or ¥134.98 per share.
For the six months ending Jun. 2015, the parent company expected to report net sales of ¥9 million, ordinary loss of ¥366 million and net loss of ¥368 million or ¥55.08 per share.
Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.
MedRx Co., Ltd Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Consolidated and Non-Consolidated Earnings Guidance for the Six Months Ending Jun. 2015 and for the Year Ending December 31, 2015